Lirum Therapeutics, Inc.(LRTX.US)

Lirum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the treatment of debilitating diseases. Its lead product candidate is LX-101, an insulin-like growth factor-1 receptor directed agent to treat patients with various cancers and autoimmune diseases, including thyroid eye disease. The company was incorporated in 2021 and is based in New York, New York.